State Street
RAPP

State Street’s Rapport Therapeutics RAPP Stock Holding History

State Street’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Buy
818,712
+59,160
+8% +$2.17M ﹤0.01% 2081
2026
Q1 		$23.8M Buy
759,552
+44,731
+6% +$1.26M ﹤0.01% 2156
2025
Q4 		$21.7M Buy
714,821
+343,195
+92% +$9.5M ﹤0.01% 2226
2025
Q3 		$11M Buy
371,626
+72,918
+24% +$1.3M ﹤0.01% 2585
2025
Q2 		$3.4M Buy
298,708
+107,586
+56% +$1.14M ﹤0.01% 3099
2025
Q1 		$1.92M Buy
191,122
+23,584
+14% +$306K ﹤0.01% 3261
2024
Q4 		$2.97M Buy
167,538
+109,492
+189% +$2.43M ﹤0.01% 3183
2024
Q3 		$1.19M Buy
+58,046
New +$1.25M ﹤0.01% 3457

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street's RAPP Position: Q2 2026 in Review

State Street increased its Rapport Therapeutics (RAPP) stake by 7.8% in Q2 2026, buying an estimated $2.17M and bringing the position to 818,712 shares worth $34.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

State Street first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • State Street held 818,712 shares of Rapport Therapeutics worth $34.1M as of Q2 2026.
  • State Street bought 59,160 Rapport Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Rapport Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2081 holding.
  • State Street first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.